RUBY Dostarlimab + CT
ENGOT-EN6-NSGO/GOG3031/RUBY: Outcomes by BICR With Addition of Dostarlimab to Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer

Released: June 09, 2023

Activity

Progress
1
Course Completed